German medical device firm joimax has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its Vaporflex and Legato electrosurgical probes with radiowave technology for open and endoscopic spine surgery.
The joimax Electrosurgical Instruments feature a series of instruments to facilitate the delivery of electrical energy from an RF generator to the patient tissue for use in cutting and/or coagulation of tissue.
All Vaporflex and Legato probes will utilize radio frequency that is produced by high oscillating electrical current secured from a commercially available RF generator.
The company optimized Vaporflex system with different lengths, diameters and probe tips to caryy out endoscopic transforaminal and interlaminar procedures.
It can be used with all Endovapor /SurgiMax and SurgiMax Plus electrosurgical units and enables an easy swap of the Triggerflex to the new Vaporflex system.
The bipolar Vaporflex probes can be easily integrated to the complete range of joimax systems.
The monopolar and bipolar Legato probes are said to support the rhizotomy procedures with the existing Multiuse and both new products MultiZYTE RT for facet joint denervation and MultiZYTE SI for SI joint therapy.
joimax CEO and founder Wolfgang Ries said: “Both the Vaporflex and Legato probes are ready for several generations of radiofrequency generators.
“Spinal surgeons are now enabled to perform the range of joimax procedures with even more flexibility and ergonomics in the USA as well. This way we further enhance surgical interventions in endoscopic minimally-invasive spinal surgery.”
Founded in 2001, joimax produces and markets complete systems for endoscopic minimally invasive spinal surgery.
Image: Joimax’s new Vaporflex system. Photo: courtesy of Business Wire.